Piper Jaffray sees Endologix’s updates as ‘positive’

Piper Jaffray analyst Matt O’Brien maintained a Neutral rating on Endologix, saying he wanted to see “more evidence of execution in the coming quarters.” The analyst added that the updates the company released this morning, including an equity raise, an exchange of convertible debt, a number of updates with the Deerfield agreement, and a reaffirmation of its FY19 revenue guidance, were a “positive,” as it showed the company has “increased financial flexibility lower debt load risk, and easier covenants.”

https://thefly.com/landingPageNews.php?id=2886887